Department of Dermatology, University of Iowa Hospitals and Clinics.
Section of Oncology, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Melanoma Res. 2021 Feb 1;31(1):98-100. doi: 10.1097/CMR.0000000000000713.
Pembrolizumab is a humanized IgG4 isotype mAb that the targets and blocks the programmed cell death protein 1 receptor on lymphocytes. Its use in treating metastatic melanoma is associated with increased overall survival compared to other older immunotherapies. Several adverse effects have been noted including both systemic and cutaneous manifestations. As a relatively novel treatment option, many new cutaneous manifestations are still being observed, occurring at various times after initiation of therapy. Previously noted cutaneous adverse effects include sarcoid-like reactions, rash, and changes in preexisting lesions or scars. Here we present a case in which biopsy-proven morphea developed after completion of pembrolizumab therapy.
帕博利珠单抗是一种人源化 IgG4 同种型单克隆抗体，可靶向并阻断淋巴细胞上的程序性细胞死亡蛋白 1 受体。与其他较老的免疫疗法相比，它在治疗转移性黑色素瘤方面可提高总生存率。已注意到多种不良反应，包括全身性和皮肤表现。作为一种相对较新的治疗选择，许多新的皮肤表现仍在观察中，在开始治疗后的不同时间发生。以前注意到的皮肤不良反应包括类肉瘤样反应、皮疹以及现有病变或疤痕的变化。在这里，我们提出了一个在完成帕博利珠单抗治疗后活检证实硬斑病发生的病例。
